Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE: Escitalopram for Remission in Depression
NCT01628783Phase 4Unknown
- Start
- Jun 2012
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Escitalopram oxalate oral solution in major depressive disorder (MDD). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 7 weeks. Status: unknown.
02
Drugs
Escitalopram oxalate oral solution
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01628783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01628783.